Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Prostate cancer is the most frequently diagnosed form of cancer in the United States. Additionally, it is the second leading cause of death in men. There were approximately 240,000 diagnoses and 28,000 deaths in the United States in 2012. Metastatic castration-resistant prostate cancer (mCRPC) makes up the majority of these deaths. This form has no known cure and a survival rate of less than two years. However, multiple new treatments and studies outline new options giving more men better prognoses and quality of life. Our associated doctors work on many of these revolutionary treatments now. They discuss their findings in more detail below.


Presentations on Metastatic Castration-Resistant Prostate Cancer

Multimodal Approach to Advanced Prostate Cancer

Martin E. Gleave, MD, FRCSC, FACS, discusses his views on improving advanced prostate cancer treatment approaches. Specifically, he emphasizes methods that integrate various treatment options beyond surgical castration and androgen deprivation therapy (ADT).

Read More

Integrating the AUA Guidelines into Your Practice

Michael S. Cookson, MD, MMHC, describes how urologists can use American Urological Association (AUA) guidelines to better manage metastatic castration resistant prostate cancer (mCRPC) patients. He stresses the importance of urologists serving as the primary caregiver, the multidisciplinary care model, and organized sequencing of treatments and therapeutics.

Read More

Immunotherapy 101 for the Urologist

Raoul S. Concepcion, MD, summarizes the mechanism of action behind the immune response to cancer. He also provides an update on the current and emerging immunotherapies for cancer treatment, including vaccines, checkpoint inhibitors, CAR T-cell therapies, viral vectors, and adoptive cell therapy.

Read More

The Benefits and Challenges (Present and Future) for the Urologist Treating mCRPC

In this talk, Lawrence I. Karsh, MD, FACS, discusses the benefits and challenges of urologists treating those with mCRPC. His practice incorporates sixteen urologists, a medical oncologist, and a radiation oncologist. He then continues his discussion detailing how his practice operates utilizing their team of physicians and therapies.

Read More

Continuing Care for Your Patients with Metastatic CRPC

Michael S. Cookson, MD, talks about the importance of continuing care for patients with metastatic castration-resistant prostate cancer via three over-arching guidelines. Number one is the importance of the urologist being the primary care giver, two being the establishment of a multi-disciplinary clinic, and three being the proper utilization of evidence-based therapeutic options.

Read More

Debate: Comparative Effectiveness of Surgery versus Radiation

Dr. Laurence Klotz and Dr. Mack Roach, III presented a debate on “Comparative Effectiveness of Surgery and Radiation: Surgery Is Better” versus “Radiotherapy Yields Better Oncologic Outcomes than Radical Prostatectomy for Clinically Localized Prostate Cancer” at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between October 14th and 16th 2016.

Read More

ADT: Mechanisms of CV Disease

E. David Crawford, MD presented “ADT: Mechanisms of CV Disease” at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between October 14th and 16th 2016.

Read More

Multimodal Treatment of mCRPC: Potential Sequencing of New Agents

Dr. Neal D. Shore spoke at the 24th International Prostate Cancer Update on Saturday, February 22, 2014 on “Multimodal Treatment of mCRPC: Potential Sequencing of New Agents.” In his presentation, Dr. Shore discusses multimodal treatment options, new agents, and the need for more data.

Read More